Massachusetts Financial Services Co. MA Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 11.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,209 shares of the medical equipment provider's stock after purchasing an additional 4,918 shares during the period. Massachusetts Financial Services Co. MA's holdings in Hologic were worth $3,040,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Beverly Hills Private Wealth LLC increased its stake in shares of Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after buying an additional 180 shares during the period. Allworth Financial LP increased its stake in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the period. Dark Forest Capital Management LP increased its stake in shares of Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after buying an additional 223 shares during the period. Baker Avenue Asset Management LP increased its stake in shares of Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after buying an additional 225 shares during the period. Finally, Integrated Advisors Network LLC increased its stake in shares of Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock valued at $346,000 after buying an additional 289 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOLX. Mizuho raised their price target on Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Raymond James Financial reiterated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Stephens cut their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic currently has an average rating of "Hold" and an average price target of $77.33.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Up 0.9%

NASDAQ HOLX traded up $0.58 during trading on Wednesday, hitting $65.95. The company's stock had a trading volume of 1,441,527 shares, compared to its average volume of 2,390,605. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The company has a market cap of $14.70 billion, a PE ratio of 27.83, a P/E/G ratio of 2.40 and a beta of 0.55. The business's 50 day simple moving average is $62.72 and its 200-day simple moving average is $63.07. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.03 earnings per share. The company's revenue was down 1.2% compared to the same quarter last year. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.